By Chris Wack
Autonomix Medical shares were up 24% to $4.10 after the company said it received a patent from the U.S. Patent and Trademark Office.
The medical device company said the patent, titled Systems and Methods for Treating Cancer and/or Augmenting Organ Function, covers technology including systems, methods and devices for interventionalply treating cancerous tumors and cancer-related pain.
The Woodlands, Texas, company said it is developing its technology to initially focus on pancreatic cancer pain relief.
A previous preclinical study showed the company's nerve ablation technique significantly reduced metastases and tumor mass in mice, highlighting the role of neural pathways in pancreatic cancer.
Autonomix said it is currently conducting a human clinical trial aimed at pain reduction via nerve ablation near the pancreas, with future studies planned to validate these preclinical results in clinical settings.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 30, 2024 13:37 ET (18:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.